Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
1. A method of treating moderate to severe eosinophilic asthma in a human in need thereof comprising orally administering to the human a therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 50 milligrams to about 600 milligrams per day and wherein eosinophilic asthma is characterized by 150 eosinophil cells or more per microliter in peripheral blood prior to administering dexpramipexole, and wherein the moderate to severe eosinophilic asthma is treated in the human.
2. The method of claim 1 , wherein the eosinophilic asthma is moderate.
3. The method of claim 1 , wherein the eosinophilic asthma is severe.
4. The method of claim 1 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
5. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
6. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.
7. The method of claim 1 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
8. The method of claim 1 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is orally administered in a solid unit dose.
9. The method of claim 1 , wherein administering comprises administering half of the daily dose twice per day.
10. The method of claim 5 , wherein administering comprises administering half of the daily dose twice per day.
11. The method of claim 6 , wherein administering comprises administering half of the daily dose twice per day.
12. The method of claim 7 , wherein administering comprises administering half of the daily dose twice per day.
13. The method of claim 1 further comprising administering a second therapeutic agent.
14. The method of claim 13 , wherein the second therapeutic agent is a corticosteroid.
15. The method of claim 1 , wherein treatment results in a decrease in eosinophil levels in the lungs.
16. The method of claim 1 , wherein treatment results in a decrease in eosinophil levels in the lower respiratory airways.
17. A method of treating eosinophilic asthma in a human in need thereof comprising orally administering to the human a therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 50 milligrams to about 600 milligrams per day and wherein eosinophilic asthma is characterized by 150 eosinophil cells or more per microliter in peripheral blood prior to administering dexpramipexole, and wherein the eosinophilic asthma is treated in the human.
18. The method of claim 17 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
19. The method of claim 17 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
20. The method of claim 17 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.
21. The method of claim 17 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
22. The method of claim 17 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is orally administered in a solid unit dose.
23. The method of claim 17 , wherein administering comprises administering half of the daily dose twice per day.
24. The method of claim 19 , wherein administering comprises administering half of the daily dose twice per day.
25. The method of claim 20 , wherein administering comprises administering half of the daily dose twice per day.
26. The method of claim 21 , wherein administering comprises administering half of the daily dose twice per day.
27. The method of claim 17 further comprising administering a second therapeutic agent.
28. The method of claim 27 , wherein the second therapeutic agent is a corticosteroid.
29. The method of claim 17 , wherein treatment results in a decrease in eosinophil levels in the lungs.
30. The method of claim 17 , wherein treatment results in a decrease in eosinophil levels in the lower respiratory airways.
31. The method of claim 1 , wherein administering comprises administering the daily dose once per day.
32. The method of claim 5 , wherein administering comprises administering the daily dose once a per day.
33. The method of claim 6 , wherein administering comprises administering the daily dose once per day.
34. The method of claim 7 , wherein administering comprises administering the daily dose once per day.
35. The method of claim 17 , wherein administering comprises administering the daily dose once per day.
36. The method of claim 19 , wherein administering comprises administering the daily dose once per day.
37. The method of claim 20 , wherein administering comprises administering the daily dose once per day.
38. The method of claim 21 , wherein administering comprises administering the daily dose once per day.
39. The method of claim 2 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
40. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
41. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.
42. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
43. The method of claim 2 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is orally administered in a solid unit dose.
44. The method of claim 2 , wherein administering comprises administering half of the daily dose twice per day.
45. The method of claim 40 , wherein administering comprises administering half of the daily dose twice per day.
46. The method of claim 41 , wherein administering comprises administering half of the daily dose twice per day.
47. The method of claim 42 , wherein administering comprises administering half of the daily dose twice per day.
48. The method of claim 2 further comprising administering a second therapeutic agent.
49. The method of claim 48 , wherein the second therapeutic agent is a corticosteroid.
50. The method of claim 2 , wherein treatment results in a decrease in eosinophil levels in the lungs.
51. The method of claim 2 , wherein treatment results in a decrease in eosinophil levels in the lower respiratory airways.
52. The method of claim 2 , wherein administering comprises administering the daily dose once a per day.
53. The method of claim 40 , wherein administering comprises administering the daily dose once per day.
54. The method of claim 41 , wherein administering comprises administering the daily dose once per day.
55. The method of claim 42 , wherein administering comprises administering the daily dose once per day.
56. The method of claim 3 , wherein the pharmaceutically acceptable salt is (6R)-4, 5, 6, 7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate.
57. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 75 milligrams per day.
58. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 150 milligrams per day.
59. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is about 300 milligrams per day.
60. The method of claim 3 , wherein the dexpramipexole or a pharmaceutically acceptable salt thereof is orally administered in a solid unit dose.
61. The method of claim 3 , wherein administering comprises administering half of the daily dose twice per day.
62. The method of claim 57 , wherein administering comprises administering half of the daily dose twice per day.
63. The method of claim 58 , wherein administering comprises administering half of the daily dose twice per day.
64. The method of claim 59 , wherein administering comprises administering half of the daily dose twice per day.
65. The method of claim 3 further comprising administering a second therapeutic agent.
66. The method of claim 65 , wherein the second therapeutic agent is a corticosteroid.
67. The method of claim 3 , wherein treatment results in a decrease in eosinophil levels in the lungs.
68. The method of claim 3 , wherein treatment results in a decrease in eosinophil levels in the lower respiratory airways.
69. The method of claim 3 , wherein administering comprises administering the daily dose once per day.
70. The method of claim 57 , wherein administering comprises administering the daily dose once a per day.
71. The method of claim 58 , wherein administering comprises administering the daily dose once per day.
72. The method of claim 59 , wherein administering comprises administering the daily dose once per day.
73. The method of claim 1 , wherein eosinophilic asthma is characterized by about 300 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
74. The method of claim 73 , wherein eosinophilic asthma is characterized by about 400 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
75. The method of claim 74 , wherein eosinophilic asthma is characterized by about 500 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
76. The method of claim 75 , wherein eosinophilic asthma is characterized by about 1000 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
77. The method of claim 76 , wherein eosinophilic asthma is characterized by about 1500 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
78. The method of claim 17 , wherein eosinophilic asthma is characterized by about 300 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
79. The method of claim 78 , wherein eosinophilic asthma is characterized by about 400 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
80. The method of claim 79 , wherein eosinophilic asthma is characterized by about 500 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
81. The method of claim 80 , wherein eosinophilic asthma is characterized by about 1000 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
82. The method of claim 81 , wherein eosinophilic asthma is characterized by about 1500 eosinophil cells or more per microliter in the peripheral blood prior to administering dexpramipexole.
83. The method of claim 1 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 50% compared to prior to administering dexpramipexole.
84. The method of claim 83 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 60% compared to prior to administering dexpramipexole.
85. The method of claim 84 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 70% compared to prior to administering dexpramipexole.
86. The method of claim 85 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 80% compared to prior to administering dexpramipexole.
87. The method of claim 86 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 90% compared to prior to administering dexpramipexole.
88. The method of claim 17 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 50% compared to prior to administering dexpramipexole.
89. The method of claim 88 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 60% compared to prior to administering dexpramipexole.
90. The method of claim 89 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 70% compared to prior to administering dexpramipexole.
91. The method of claim 90 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 80% compared to prior to administering dexpramipexole.
92. The method of claim 91 , wherein the eosinophil cells in the peripheral blood in the human are reduced by at least 90% compared to prior to administering dexpramipexole.
93. The method of claim 2 , wherein administering comprises administering one third of the daily dose three times per day.
94. The method of claim 40 , wherein administering comprises administering one third of the daily dose three times per day.
95. The method of claim 41 , wherein administering comprises administering one third of the daily dose three times per day.
96. The method of claim 42 , wherein administering comprises administering one third of the daily dose three times per day.
97. The method of claim 3 , wherein administering comprises administering one third of the daily dose three times per day.
98. The method of claim 57 , wherein administering comprises administering one third of the daily dose three times per day.
99. The method of claim 58 , wherein administering comprises administering one third of the daily dose three times per day.
100. The method of claim 59 , wherein administering comprises administering one third of the daily dose three times per day.
101. The method of claim 2 , wherein administering comprises administering one fourth of the daily dose four times per day.
102. The method of claim 40 , wherein administering comprises administering one fourth of the daily dose four times per day.
103. The method of claim 41 , wherein administering comprises administering one fourth of the daily dose four times per day.
104. The method of claim 42 , wherein administering comprises administering one fourth of the daily dose four times per day.
105. The method of claim 3 , wherein administering comprises administering one fourth of the daily dose four times per day.
106. The method of claim 57 , wherein administering comprises administering one fourth of the daily dose four times per day.
107. The method of claim 58 , wherein administering comprises administering one fourth of the daily dose four times per day.
108. The method of claim 59 , wherein administering comprises administering one fourth of the daily dose four times per day.
109. The method of claim 2 , wherein administering comprises administering one fifth of the daily dose five times per day.
110. The method of claim 40 , wherein administering comprises administering one fifth of the daily dose five times per day.
111. The method of claim 41 , wherein administering comprises administering one fifth of the daily dose five times per day.
112. The method of claim 42 , wherein administering comprises administering one fifth of the daily dose five times per day.
113. The method of claim 3 , wherein administering comprises administering one fifth of the daily dose five times per day.
114. The method of claim 57 , wherein administering comprises administering one fifth of the daily dose five times per day.
115. The method of claim 58 , wherein administering comprises administering one fifth of the daily dose five times per day.
116. The method of claim 59 , wherein administering comprises administering one fifth of the daily dose five times per day.
117. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 50 milligrams per day to about 300 milligrams per day.
118. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 100 milligrams per day to about 600 milligrams per day.
119. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 150 milligrams per day to about 300 milligrams per day.
120. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 150 milligrams per day to about 600 milligrams per day.
121. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 300 milligrams per day to about 500 milligrams per day.
122. The method of claim 2 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 300 milligrams per day to about 600 milligrams per day.
123. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 50 milligrams per day to about 300 milligrams per day.
124. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 100 milligrams per day to about 600 milligrams per day.
125. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 150 milligrams per day to about 300 milligrams per day.
126. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 150 milligrams per day to about 600 milligrams per day.
127. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 300 milligrams per day to about 500 milligrams per day.
128. The method of claim 3 , wherein the therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof, is in a range between about 300 milligrams per day to about 600 milligrams per day.